Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. - Kileel EM; Malvestutto CD; Zanni MV; Davies-Smith E; Fichtenbaum CJ; Lake JE; Lo J; Aberg JA; Martinez E; Patel K; Bloomfield GS; Chu SM; et al. (The lancet. HIV, 2026)